PMID- 12700504
OWN - NLM
STAT- MEDLINE
DCOM- 20030606
LR  - 20201208
IS  - 0399-8320 (Print)
IS  - 0399-8320 (Linking)
VI  - 27
IP  - 3 Pt 2
DP  - 2003 Mar
TI  - [First line therapy for Helicobacter pylori eradication in France].
PG  - 467-72
AB  - The available results of triple therapy for the eradication of Helicobacter 
      pylori (H. pylori), as recommended in European countries--i.e. combination of 
      proton pump inhibitor (PPI) and two antibiotics among amoxicillin, 
      clarithromycin, metronidazole for 7 days--lead to rates of failure of about 30%. 
      Several clinical studies have been recently conducted to distinguish factors 
      influencing effectiveness of therapy and to evaluate results of new regimens. 
      Comparative trials have demonstrated the equivalence of omeprazole 20 mg, 
      lansoprazole 30 mg, pantoprazole 40 mg, rabeprazole 20 mg and esomeprazole 20 mg, 
      twice daily in these 7-days triple therapies. Efficacy of treatment is not 
      affected by metronidazole resistance (44% in France) when 
      amoxicillin-clarithromycin-based triple therapy is prescribed. The impact of 
      clarithromycin resistance (14%) is much more important with failure of 
      eradication in all cases treated by clarithromycin-based triple therapy. The 
      eradication rate could be slightly improved by increasing the dose of 
      clarithromycin but with more frequent side effects. To prolong the duration 
      treatment improve also slightly the cure rate with a gain of less than 10%, but 
      with an increasing rate of side effects. To date, the PPI-based triple therapies, 
      as recommended in France, have not to be modified. The treatment of H. pylori 
      infection has to be globally considered, with a first-line treatment leading to 
      eradication in 70% of patients and a second-line treatment needed for the resting 
      30% of patients.
FAU - Dupas, Jean-Louis
AU  - Dupas JL
AD  - Service d'Hepato-Gastroenterologie, Hopital Nord, 80054 Amiens Cedex. 
      dupas.jean-louis@chu-amiens.fr
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Comment eradiquer Helicobacter pylori en premiere intention en France?
PL  - France
TA  - Gastroenterol Clin Biol
JT  - Gastroenterologie clinique et biologique
JID - 7704825
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Penicillins)
RN  - 140QMO216E (Metronidazole)
RN  - 804826J2HU (Amoxicillin)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - Amoxicillin/administration & dosage/*pharmacology
MH  - Anti-Bacterial Agents/administration & dosage/*pharmacology
MH  - Clarithromycin/administration & dosage/*pharmacology
MH  - Drug Administration Schedule
MH  - Drug Resistance
MH  - Drug Therapy, Combination
MH  - France
MH  - Helicobacter Infections/*drug therapy/pathology
MH  - Helicobacter pylori/drug effects/*pathogenicity
MH  - Humans
MH  - Metronidazole/administration & dosage/*pharmacology
MH  - Penicillins/administration & dosage/*pharmacology
MH  - *Practice Guidelines as Topic
MH  - Recurrence
RF  - 67
EDAT- 2003/04/18 05:00
MHDA- 2003/06/07 05:00
CRDT- 2003/04/18 05:00
PHST- 2003/04/18 05:00 [pubmed]
PHST- 2003/06/07 05:00 [medline]
PHST- 2003/04/18 05:00 [entrez]
AID - MDOI-GCB-03-2003-27-3-C2-0399-8320-101019-ART14 [pii]
PST - ppublish
SO  - Gastroenterol Clin Biol. 2003 Mar;27(3 Pt 2):467-72.